BioCentury | Feb 13, 2021
Management Tracks

New venture partners at SR One; plus moves at Surface Oncology, Agenus, AbCellera, BioDelivery, Transcenta, Dewpoint, Cortexyme, Cerevance and Penrose

SR One named Chris Chai and Peter Van Vlasselaer venture partners. Chai was CFO of Principia Biopharma Inc., which Sanofi (Euronext:SAN; NASDAQ:SNY) acquired last year for $3.4 billion. Van Vlasselaer was most recently founder, president, and CEO...
BioCentury | May 15, 2013
Financial News

Third Rock names new venture partners

Healthcare VC firm Third Rock Ventures named John Maraganore, CEO of RNAi company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), a venture partner. Third Rock also named Daniel Lynch and Steven Paul as venture partners. Lynch joined Third...
BioCentury | May 8, 2000
Emerging Company Profile

Myogen Inc.

...Investors: Sequel Venture Partners, Crosspoint Venture Partners, InterWest Partners, New Enterprise Associates, CMEA Ventures, and New Venture Partners...
Items per page:
1 - 3 of 3
BioCentury | Feb 13, 2021
Management Tracks

New venture partners at SR One; plus moves at Surface Oncology, Agenus, AbCellera, BioDelivery, Transcenta, Dewpoint, Cortexyme, Cerevance and Penrose

SR One named Chris Chai and Peter Van Vlasselaer venture partners. Chai was CFO of Principia Biopharma Inc., which Sanofi (Euronext:SAN; NASDAQ:SNY) acquired last year for $3.4 billion. Van Vlasselaer was most recently founder, president, and CEO...
BioCentury | May 15, 2013
Financial News

Third Rock names new venture partners

Healthcare VC firm Third Rock Ventures named John Maraganore, CEO of RNAi company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), a venture partner. Third Rock also named Daniel Lynch and Steven Paul as venture partners. Lynch joined Third...
BioCentury | May 8, 2000
Emerging Company Profile

Myogen Inc.

...Investors: Sequel Venture Partners, Crosspoint Venture Partners, InterWest Partners, New Enterprise Associates, CMEA Ventures, and New Venture Partners...
Items per page:
1 - 3 of 3